论文部分内容阅读
目的探讨骨桥蛋白(OPN)在乳腺癌组织中的表达及其与临床病理和p53的关系。方法采用MaxVision免疫组化法检测125例乳腺癌标本和20例正常乳腺组织OPN表达,分析其与p53和临床病理因素的相关性。结果 OPN在乳腺癌的阳性表达率为62.4%,正常乳腺组织基本无OPN表达。OPN在不同肿瘤大小和有无腋窝淋巴结转移的患者间差异具有统计学意义(P<0.05)。OPN的阳性表达率随临床病理分期的增加显著升高,OPN表达与p53呈显著正相关(r=0.297,P<0.05)。结论 OPN在乳腺癌组织中高表达。其表达与肿瘤分期分级及转移密切相关。OPN阳性表达可作为评价乳腺癌发生、发展的生物学指标;联合p53检测更有助于乳腺癌病情的评估及预后的判断。
Objective To investigate the expression of osteopontin (OPN) in breast cancer and its relationship with clinicopathology and p53. Methods MaxVision immunohistochemistry was used to detect the expression of OPN in 125 cases of breast cancer specimens and 20 cases of normal breast tissues. The correlation between OPN expression and clinicopathological factors was analyzed. Results The positive rate of OPN expression in breast cancer was 62.4%, while the expression of OPN in normal breast tissue was almost no. The difference of OPN between patients with different tumor size and with or without axillary lymph node metastasis was statistically significant (P <0.05). The positive expression rate of OPN was significantly increased with the increase of clinical pathological stage. The expression of OPN was positively correlated with p53 (r = 0.297, P <0.05). Conclusion OPN is highly expressed in breast cancer tissues. Its expression is closely related to tumor staging and metastasis. The positive expression of OPN can be used as a biological indicator to evaluate the occurrence and development of breast cancer. Combined detection of p53 is more helpful to evaluate the prognosis of breast cancer.